Sonoma Pharmaceuticals enters into ATM equity distribution agreement with Maxim Group for up to $392,077

Sonoma Pharmaceuticals, Inc.

ATM facility allows Sonoma to sell up to $392,077 of common stock through Maxim Group.
Maxim receives 3% commission per sale plus expense reimbursement up to $20,000.
Sales under effective S-3 registration statement (333-275311) declared effective Nov 20, 2023.
Company not obligated to sell any shares; no assurance of price, timing, or amount.
Agreement terminates upon full sale of shares or earlier per its terms.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Sonoma Pharmaceuticals, Inc. entered into Equity Distribution Agreement with Maxim Group LLC valued at up to $392,077 (effective 2023-12-15).

Action: entry
Agreement: atm program
Counterparty: Maxim Group LLC
Value: up to $392,077
Effective: 2023-12-15

Exact text from the filing

On December 15, 2023, Sonoma Pharmaceuticals, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”), with Maxim Group LLC (“Maxim”), pursuant to which the Company may offer and sell, from time to time, through Maxim, as sales agent or principal, shares of its common stock, $0.0001 par value per share.

View on SEC.gov

737 material agreements filed in the last 30 days. Browse all material agreements →

Sonoma Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-008898

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.